Clinical beta
FMBM is currently in clinical beta. Content is for professional review/testing and must not replace local protocols, senior clinical judgment, or official prescribing references.
Drug Monograph
Piperacillin–Tazobactam
Antipseudomonal ureidopenicillin + β-lactamase inhibitor
Indication
Sepsis / septic shock • HAP/VAP • Complicated intra-abdominal • Complicated UTI / urosepsis • Polymicrobial SSTI / DFI
INDICATIONS (CORE USE)
Sepsis / septic shock • HAP/VAP • Complicated intra-abdominal • Complicated UTI / urosepsis • Polymicrobial SSTI / DFI
ADULT DOSE (STANDARD)
4.5 g IV q6–8h Severe/ICU: 4.5 g q6h (extended infusion preferred)
MAX DOSE
Max: 4.5 g q6h (18 g piperacillin/day) — adjust in renal impairment
Route
IV only
PEDIATRIC DOSE
100 mg/kg/dose (piperacillin component) IV q8h (per pediatric reference)
Must-not-miss safety points
Major warning
- Severe β-lactam hypersensitivity (anaphylaxis risk) - AKI risk (↑ with vancomycin) - Renal toxicity (dose-dependent accumulation) - Neurotoxicity (high exposure or renal failure) - Do NOT mix with aminoglycosides (IV inactivation) - Time-dependent killing → infusion strategy matters
USE IF: Sepsis or septic shock (empiric); hospital-acquired or ventilator-associated pneumonia; complicated intra-abdominal infection; polymicrobial SSTI or diabetic foot infection when broad IV Gram-negative and antipseudomonal β-lactam coverage is indicated. AVOID IF: Severe penicillin allergy; ESBL or AmpC-confirmed infection where a carbapenem (or culture-directed alternative) is preferred; avoid unnecessary prolonged broad-spectrum use (resistance risk). Piperacillin–tazobactam is an IV-only antipseudomonal ureidopenicillin plus β-lactamase inhibitor—pair stewardship, renal dosing, and infusion duration with severity and culture data.
ADULT DOSE
Standard: 4.5 g IV q6–8h. Severe / ICU: 4.5 g IV q6h. Oral formulation not available.
PEDIATRIC DOSE
100 mg/kg/dose (piperacillin component) IV q8h (per pediatric reference) — verify product ratio and maximum daily exposure.
MAX DOSE
Max: 4.5 g q6h (18 g/day piperacillin) — reduce dose and/or extend interval in renal impairment per labeling.
Practical Note
- Renal: dose-adjust by CrCl - Hemodialysis: post-HD dosing required - Hepatic: no routine adjustment - β-lactam: time-dependent killing → extended infusion improves PK/PD target attainment - Separate from aminoglycosides (IV inactivation)
Clinical warnings
Adverse effects
Pediatrics
100 mg/kg/dose (piperacillin component) IV q8h (per pediatric reference)
Pregnancy
Generally used when indicated in pregnancy; follow current product labeling and obstetric guidance. Breastfeeding usually compatible with monitoring for infant GI symptoms. Generally considered safe when clinically indicated; align with current labeling and obstetric guidance. Breastfeeding usually compatible — monitor infant.
Lactation
See lactation references and product labeling.
Renal impairment
Mandatory dose adjustment by creatinine clearance; neurotoxicity and accumulation risk if under-adjusted.
Hepatic impairment
No routine dose reduction; monitor LFTs and coagulation when clinically relevant.
Elderly
Dose by CrCl; higher AKI and drug-interaction risk.
IV only. Standard infusion ~30 minutes. Extended infusion (3–4 h) preferred in ICU/sepsis when feasible. Do NOT mix with aminoglycosides in the same solution or Y-site — use separate lines and flush.
Clinical Picture
High exposure (especially renal failure) → neurotoxicity (confusion, seizures) ± AKI
Immediate Actions
- Stop drug - Supportive care - Hydration - Monitor renal function and electrolytes
Antidote
No specific antidote — supportive care
Decontamination
Not applicable to typical IV use — poison center for massive error.
Escalation
IV fluids; benzodiazepines for seizures; hemodialysis may enhance clearance in severe cases per nephrology.
Common mistakes, resistance logic, and bedside traps
FIRST LINE: Broad-spectrum IV antipseudomonal β-lactam for severe infections. DOSE — Standard 4.5 g IV q6–8h; severe/ICU 4.5 g q6h (extended infusion preferred). MAX — 4.5 g q6h (18 g piperacillin/day; adjust in renal impairment). AVOID — Renal impairment without adjustment; prolonged use without de-escalation. ANTIDOTE — None.
- Must adjust for CrCl <50 - AKI risk ↑ with vancomycin - Neurotoxicity in renal failure - No oral formulation - Reassess broad-spectrum need daily - De-escalate early once cultures available - Extended infusion improves PK/PD target attainment
First-line empiric option in many septic shock pathways. Extended infusion preferred in ICU/sepsis. Reassess at 48–72 h → de-escalate. Avoid unnecessary prolonged broad-spectrum use. Avoid reflex vancomycin combination unless indicated. Neurotoxicity should prompt renal dosing review. Not reliable definitive therapy for ESBL/AmpC without susceptibility support.
- Bioavailability: IV only - Distribution: wide (lung, abdomen, urine) - Protein binding: low–moderate - Elimination: renal - t½ prolonged in renal impairment - β-lactam: time-dependent killing
Piperacillin inhibits penicillin-binding proteins and bacterial cell wall synthesis. Tazobactam inhibits many class A and some extended-spectrum β-lactamases, restoring activity against susceptible β-lactamase–producing organisms.
Saudi Arabia
Tazocin, Yanoven
Global
Zosyn
Common trade names are curated examples only — formulations and availability vary. Verify the exact product name with your local pharmacy and national regulator before prescribing or dispensing.
Saudi Arabia
International